Testing a new MRI method for solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the reproducibility of hyperpolarized pyruvate MRI scans in patients with malignant solid tumors. Participants will undergo two MRI scans using hyperpolarized pyruvate to determine if the results can be consistently reproduced. The findings from these scans will be compared to pathological results obtained from surgery to assess the additional insights provided by this imaging technique regarding tumor metabolism. The study focuses on various types of solid tumors, including sarcoma, prostate, breast, brain, metastatic, and pancreatic cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for patients with brain lesions. Patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmation.
* Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm in the long axis and/or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment.
* Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards \& Guidelines), from assays obtained \< 2 weeks prior to study enrollment.
* This study will include only patients with sarcoma, prostate, breast, brain, metastatic or pancreatic cancer. In the future other patient groups may be included through amendment of this protocol.

Exclusion Criteria:

* Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of \[1-13C\] pyruvate injection)
* Breast-feeding
* Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
* Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
* Bilirubin \> 1.5 x (ULN)
* AST/ALT \>2.5 x ULN
* Albumin \< 3 g/dl
* GGT \> 2.5 x ULN if Alkaline phosphatase \> 2.5 x ULN.
* Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 3-4 weeks prior to study enrollment
* Acute major illness (e.g., unstable cardiovascular condition, etc.)
* Standard MRI exclusion criteria will also be applied, including pacemakers and metal clips located in the patient.

Where it's running

• Memorial Sloan Kettering Bergen (Consent only )
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Kayvan Keshari, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Kayvan Keshari, PhD
• Phone: 646-888-3631

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• TAK-505 treatment for adults with advanced solid tumors

  This trial will test TAK-505, an experimental drug, in adults with locally advanced or metastatic solid tumors (such as stomach, colorectal, non-small cell lung, and head and neck cancers) who have limited standard treatment options.

  Recruiting at 13 sites Phase 1/2 Takeda · Orange, California and 14 other locations · NCT07436728

• SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

  This study will test whether giving SHR-7787 together with other anti-cancer medicines is safe and helps people with unresectable malignant solid tumors.

  Recruiting at 2 sites Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07268040

• SHR-4298 Injection for Malignant Solid Tumors: a Phase I/II study

  This study tests SHR-4298 injections in adults with advanced solid tumors to see if it is safe, tolerable, and has signs of activity.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07229612

• SHR-4849 combined with other cancer drugs for malignant solid tumors

  This study will test whether adding SHR-4849 to other cancer drugs is safe and can help adults with malignant solid tumors.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07028281

• JCXH-211 injections with anti-PD-1 therapy for malignant solid tumors

  This study tests whether injecting JCXH-211 directly into tumors, together with an anti-PD-1 medicine, is safe and tolerable in adults with malignant solid tumors.

  Recruiting Phase 1/2 Immorna Biotherapeutics, Inc. · Guangzhou, Guangdong · NCT06781125

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.